Patients with non-secretory myeloma, a disease affecting a relatively small number of individuals, can face obstacles including difficulties in receiving a diagnosis, a scarcity of available clinical ...

The FDA has started a priority review of iberdomide as an add-on to Johnson & Johnson and Genmab's anti-CD38 antibody Darzalex (daratumumab) and dexamethasone, a standard regimen for relapsed or ...

Hepta refractory multiple myeloma is marked by antigen loss, genomic complexity, and 12.8 month median survival in multi centre data.

Genetically modified immune cells can offer precious additional time to patients with advanced multiple myeloma. However, ...

Carfilzomib prevented BCMA degradation, increased target density, and improved CAR T susceptibility by ~26%–28% in vitro, while enhancing xenograft antitumor activity without worsening T-cell ...

While it’s not as well-known as, say, leukemia or melanoma, multiple myeloma is the second most common blood cancer in adults, according to the Cancer Research Institute. “Multiple myeloma is a cancer ...

The U.S. Food and Drug Administration (FDA) has accepted a new drug application for iberdomide combined with Darzalex ...

Are an adult with relapsed or refractory multiple myeloma Have tried at least four previous lines of treatments for multiple myeloma, including: Immune system modulators (help boost the immune system ...

C4 Therapeutics (NASDAQ:CCCC) executives outlined plans to advance their lead multiple myeloma program and expand the company ...

A blood test is a medical procedure where a sample of a person's blood is taken (called a blood draw) and sent to a lab for analysis. Knowing the results of blood tests helps a physician better ...

How Does Multiple Myeloma Impact the Kidneys? Multiple myeloma is a cancer of plasma cells, a type of immune cell found in bone marrow. Healthy plasma cells make proteins called antibodies to fight ...